RxDoctor Payments Data

Cecilia Soriano-Casaclang

Neonatal-Perinatal Medicine · Montclair, CANPI 1932206067

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $138 of the $154 with a category attached, or 89.1%. Abiomed accounts for 88.0% of it on its own, with 1 other manufacturer making up the rest.

$154in general payments, 2019–2025

Across 5 payments — averaging $30.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$136
  • GSK$19
$3,993,168in research payments, 2019–2025

Across 157 payments — averaging $25,434 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$3.1M
  • Pfizer$866K
  • Boehringer Ingelheim International GmbH$3K
  • Sanofi Pasteur Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$187
  • Innopharma, Inc.$114

What the payments were for

  • Travel & lodging$1711%
  • Food & beverage$13889%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed4$136
GSK1$19

How this compares

$154 in reported general payments places this provider in the 65th percentile of 371 neonatal-perinatal medicine providers in California.

See all neonatal-perinatal medicine providers in California

Other neonatal-perinatal medicine in Montclair

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →